Professional
Added to YB: 2025-12-05
Pitch date: 2025-10-30
LGND [neutral]
Ligand Pharmaceuticals Incorporated
+18.32%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.
Market Cap
$4.4B
Pitch Price
$187.78
Price Target
250.00 (+13%)
Dividend
N/A
EV/EBITDA
18.17
P/E
29.50
EV/Sales
14.96
Sector
Pharmaceuticals
Category
growth
Show full summary:
Summers Value Partners Portfolio Holding: Ligand Pharmaceuticals Incorporated
LGND (holding update): Royalty aggregator w/ capital-light model. Ohtuvaryre (COPD) & Filspari (nephropathy) exceeding expectations, Ohtuvaryre among strongest pharma launches recently. Both expected to reach $1B+ blockbuster status. Dec analyst day likely to raise long-term targets. $250 price target.
Read full article (1 min)